Skip to main content

Advertisement

SpringerLink
Log in

Visual function tests including the role of optical coherence tomography in neurofibromatosis 1

  • Annual issue paper
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Optic pathway glioma (OPG) is a common and significant complication of neurofibromatosis 1 (NF-1) that might lead to vision loss. The main reason to treat OPG is to preserve vision. Tumor location along the visual pathway largely dictates the presenting signs and symptoms. Clinical ophthalmic evaluation is focused on optic nerve functions including evaluation of pupils’ reaction to light, visual acuity, color vision, and visual field, as well as optic nerve appearance. An important relatively new ancillary test is optic coherence tomography (OCT) that measures the volume of retinal nerve fiber layer around the optic nerve and the ganglion cell layer-inner plexiform layer (GCL-IPL) of the macula, both proved to be strongly associated with losing vision in OPG. Accurate evaluation of vision functions plays a critical role in the decision of treatment. In this review, we describe the ophthalmological assessment including new biomarkers in clinical use. We also outline prognostic factors and current recommendations for surveillance and indications for treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 4
Fig. 3

Similar content being viewed by others

References

  1. Astrup J (2003) Natural history and clinical management of optic pathway glioma. Br J Neurosurg 17:327–335. https://doi.org/10.1080/02688690310001601216

    Article  CAS  PubMed  Google Scholar 

  2. Avery RA, Cnaan A, Schuman JS, Trimboli-Heidler C, Chen CL, Packer RJ, Ishikawa H (2015) Longitudinal change of circumpapillary retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2015.07.036

  3. Avery RA, Fisher MJ, Liu GT (2011) Optic pathway gliomas. J Neuro-Ophthalmology 31:269–278. https://doi.org/10.1097/WNO.0b013e31822aef82

    Article  Google Scholar 

  4. Avery RA, Hwang EI, Ishikawa H, Acosta MT, Hutcheson KA, Santos D, Zand DJ, Kilburn LB, Rosenbaum KN, Rood BR, Schuman JS, Packer RJ (2014) Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. JAMA Ophthalmol 132:265–271. https://doi.org/10.1001/jamaophthalmol.2013.7649

    Article  PubMed  PubMed Central  Google Scholar 

  5. Avery RA, Liu GT, Fisher MJ, Quinn GE, Belasco JB, Phillips PC, Maguire MG, Balcer LJ (2011) Retinal nerve fiber layer thickness in children with optic pathway gliomass. Am J Ophthalmol 151:542–549.e2. https://doi.org/10.1016/j.ajo.2010.08.046

    Article  PubMed  PubMed Central  Google Scholar 

  6. Avery RA, Mansoor A, Idrees R, Trimboli-Heidler C, Ishikawa H, Packer RJ, Linguraru MG (2016) Optic pathway glioma volume predicts retinal axon degeneration in neurofibromatosis type 1. Neurology 87:2403–2407. https://doi.org/10.1212/WNL.0000000000003402

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Awdeh RM, Kiehna EN, Drewry RD, Kerr NC, Haik BG, Wu S, Xiong X, Merchant TE (2012) Visual outcomes in pediatric optic pathway glioma after conformal radiation therapy. Radiat Oncol Biol 84:46–51. https://doi.org/10.1016/j.ijrobp.2011.10.067

    Article  Google Scholar 

  8. Balcer LJ, Liu GT, Heller G, Bilaniuk L, Volpe NJ, Galetta SL, Molloy PT, Phillips PC, Janss AJ, Vaughn S, Maguire MG (2001) Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging. Am J Ophthalmol. https://doi.org/10.1016/S0002-9394(00)00852-7

  9. Beres SJ, Avery RA (2017) Optic pathway gliomas secondary to neurofibromatosis type 1. Semin Pediatr Neurol 24:92–99. https://doi.org/10.1016/j.spen.2017.04.006

    Article  PubMed  Google Scholar 

  10. Birch J, Platts C (1993) Colour vision screening in children: an evaluation of three pseudoisochromatic tests. Ophthalmic Physiol Opt 13:344–349

    Article  CAS  Google Scholar 

  11. de Blank PMK, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA (2017) Optic pathway gliomas in neurofibromatosis type 1: an update: surveillance, treatment indications, and biomarkers of vision. J Neuroophthalmol 37:S23–S32. https://doi.org/10.1097/WNO.0000000000000550

    Article  PubMed  PubMed Central  Google Scholar 

  12. Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE (2004) Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet 127A:224–229. https://doi.org/10.1002/ajmg.a.20650

    Article  CAS  PubMed  Google Scholar 

  13. Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, Hukin J, Bartels U, Foreman N, Kellie S, Hilden J, Etzl M, Wilson B, Stephens D, Tabori U, Baruchel S (2012) Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol 30:1358–1363. https://doi.org/10.1200/JCO.2011.34.5843

    Article  CAS  PubMed  Google Scholar 

  14. Campen CJ, Gutmann DH (2018) Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol 33:73–81. https://doi.org/10.1177/0883073817739509

    Article  PubMed  PubMed Central  Google Scholar 

  15. Chang BCM, Mirabella G, Yagev R, Banh M, Mezer E, Parkin PC, Westall CA, Buncic JR (2007) Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials. Invest Ophthalmol Vis Sci 48:2895–2902. https://doi.org/10.1167/iovs.06-0429

    Article  PubMed  Google Scholar 

  16. Chang L, El-Dairi MA, Frempong TA, Burner EL, Bhatti MT, Young TL, Leigh F (2010) Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS 14:511–517. https://doi.org/10.1016/j.jaapos.2010.08.014

    Article  PubMed  Google Scholar 

  17. Dalla Via P, Opocher E, Luisa Pinello M, Calderone M, Viscardi E, Clementi M, Antonio Battistella P, Maria Laverda A, Da Dalt L, Perilongo G (2007) Neuro-oncology visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro-Oncology 9:430–437. doi: https://doi.org/10.1215/15228517-2007-031

  18. Deliganis AV, Geyer JR, Berger MS (1996) Prognostic significance of type 1 neurofibromatosis (von Recklinghausen disease) in childhood optic glioma. Neurosurgery 38:1114–1119. https://doi.org/10.1097/00006123-199606000-00010

    Article  CAS  PubMed  Google Scholar 

  19. Dobson V, Quinn GE, Balder JD, Hardy RJ, Reynolds JD, Siatkowski RM, Trese MT, Tung B (1997) Agreement between grating acuity at age 1 year and Snellen acuity at age 5.5 years in the preterm child. Investig Ophthalmol Vis Sci 38:496–503

    Google Scholar 

  20. Doro D (1990) Optic neuropathies: diagnostic role of standardized echography. Metab Pediatr syst Opthalmol 13:67–71

    CAS  Google Scholar 

  21. Estrada M, Kelly JP, Wright J, Phillips JO, Weiss A (2019) Visual function, brain imaging, and physiological factors in children with asymmetric nystagmus due to chiasmal gliomas. doi: https://doi.org/10.1016/j.pediatrneurol.2019.03.021

  22. Evans DGR, Salvador H, Chang VY, Erez A, Voss SD, Druker H, Scott HS, Tabori U (2017) Cancer and central nervous system tumor surveillance in pediatric neurofibromatosis 2 and related disorders. Clin Cancer Res 23:e54–e61. https://doi.org/10.1158/1078-0432.CCR-17-0590

    Article  CAS  PubMed  Google Scholar 

  23. Falzon K, Drimtzias E, Picton S, Simmons I (2018) Clinical science visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort Leeds Teaching Hos. Br J Ophthalmol 102:1367–1371. https://doi.org/10.1136/bjophthalmol-2017-311305

    Article  PubMed  Google Scholar 

  24. Fangusaro J, Onar-thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011–1022. doi: https://doi.org/10.1016/S1470-2045(19)30277-3

  25. Fard MA, Fakhree S, Eshraghi B (2013) Correlation of optical coherence tomography parameters with clinical and radiological progression in patients with symptomatic optic pathway gliomas. Graefes Arch Clin Exp Ophthalmol 251:2429–2436. https://doi.org/10.1007/s00417-013-2394-4

    Article  PubMed  Google Scholar 

  26. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, Kirby A (2007) Guidelines for the diagnosis and management of individuals with neurofibromatosis. J Med Genet 44:81–88. https://doi.org/10.1136/jmg.2006.045906

    Article  CAS  PubMed  Google Scholar 

  27. Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT (2013) Functional outcome measures for NF1-associated optic pathway glioma clinical trials

  28. Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT (2012) Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-Oncology 14:790–797. https://doi.org/10.1093/neuonc/nos076

    Article  PubMed  PubMed Central  Google Scholar 

  29. Gayre GS, Scott IU, Feuer W, Saunders TG, Michael Siatkowski R (2001) Long-term visual outcome in patients with anterior visual pathway gliomas. J Neuro-Ophthalmology. https://doi.org/10.1097/00041327-200103000-00001

  30. Grill J, Laithier Â, Ronique Laithier V, Rodriguez D, Raquin M-A, Pierre-Kahn A, Kalifa C (2000) When do children with optic pathway tumours need treatment ? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159:692–696. https://doi.org/10.1007/s004310000531

    Article  CAS  PubMed  Google Scholar 

  31. Gu S, Glaug N, Cnaan A, Packer RJ, Avery RA (2014) Ganglion cell layer-inner plexiform layer thickness and vision loss in young children with optic pathway gliomas. Investig Ophthalmol Vis Sci 55:1402–1408. https://doi.org/10.1167/iovs.13-13119

    Article  Google Scholar 

  32. Hawkins C, Walker E, Mohamed N (2011) BRAF-KIAA1549 Fusion predicts better clinical outcome in pediatric low-grade astrocytoma. 4790–4798. doi: https://doi.org/10.1158/1078-0432.CCR-11-0034

  33. Hepokur M, Sarici AM (2018) Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas. Graefes Arch Clin Exp Ophthalmol 256:1757–1765. https://doi.org/10.1007/s00417-018-4007-8

    Article  PubMed  Google Scholar 

  34. Iannaccone A, McCluney RA, Brewer VR, Spiegel PH, Taylor JS, Kerr NC, Pivnick EK (2002) Visual evoked potentials in children with neurofibromatosis type 1. Doc Ophthalmol 105:63–81. https://doi.org/10.1023/a:1015719803719

    Article  PubMed  Google Scholar 

  35. Jay WM (2016) Neuro-ophthalmology illustrated, 2nd edition by Valérie Biousse and Nancy J. Newman. Taylor & Francis, New York

  36. Kalin-Hajdu E, Décarie J-C, Marzouki M, Carret A-S, Ospina LH (2014) Visual acuity of children treated with chemotherapy for optic pathway gliomas. Pediatr Blood Cancer 61:223–227. https://doi.org/10.1002/pbc.24726

    Article  CAS  PubMed  Google Scholar 

  37. Kaufman LM, Doroftei O (2006) Optic glioma warranting treatment in children. Eye. Nature Publishing Group, pp 1149–1164

  38. Kelly JP, Leary S, Khanna P, Weiss AH (2012) Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas. Ophthalmology 119:1231–1237. https://doi.org/10.1016/j.ophtha.2011.12.035

    Article  PubMed  Google Scholar 

  39. Kelly JP, Weiss AH (2006) Comparison of pattern visual-evoked potentials to perimetry in the detection of visual loss in children with optic pathway gliomas. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus 10:298–306. https://doi.org/10.1016/j.jaapos.2006.02.003

    Article  Google Scholar 

  40. King A, Listernick R, Charrow J, Piersall L, Gutmann DH (2003) Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet 122A:95–99. https://doi.org/10.1002/ajmg.a.20211

    Article  PubMed  Google Scholar 

  41. Kornreich L, Blaser S, Schwarz M, Shuper A, Vishne TH, Cohen IJ, Faingold R, Michovitz S, Koplewitz B, Horev G (2001) Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis. Am J Neuroradiol

  42. Lewis RA, Gerson LP, Axelson KA, Riccardi VM, Whitford RP (1984) von Recklinghausen neurofibromatosis: II. Incidence of optic gliomata. Ophthalmology 91:929–935. https://doi.org/10.1016/S0161-6420(84)34217-8

    Article  CAS  PubMed  Google Scholar 

  43. Listernick R, Charrow JGD (2001) Letter to the editor comments on neurofibromatosis 1 and optic pathway tumors. Am J Med Genet 105:60614

    Google Scholar 

  44. Listernick R, Charrow J, Greenwald M, Mets M (1994) Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr. https://doi.org/10.1016/S0022-3476(94)70122-9

  45. Listernick R, Charrow J, Greenwald MJ, Esterly NB (1989) Optic gliomas in children with neurofibromatosis type 1. J Pediatr 114:788–792. https://doi.org/10.1016/S0022-3476(89)80137-4

    Article  CAS  PubMed  Google Scholar 

  46. Listernick R, Ferner RE, Liu GT, Gutmann DH (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61:189–198. https://doi.org/10.1002/ana.21107

    Article  CAS  PubMed  Google Scholar 

  47. Listernick R, Ferner RE, Piersall L, Sharif S, Gutmann DH, Charrow J (2004) Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 63:1944–1946. https://doi.org/10.1212/01.WNL.0000144341.16830.01

    Article  CAS  PubMed  Google Scholar 

  48. Listernick R, Louis DN, Packer RJ, Gutmann DH (1997) Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force. Ann Neurol 41:143–149. https://doi.org/10.1002/ana.410410204

    Article  CAS  PubMed  Google Scholar 

  49. Liu GT, Brodsky MC, Phillips PC, Belasco J, Janss A, Golden JC, Bilaniuk LL, Burson GT, Duhaime AC, Sutton LN (2004) Optic radiation involvement in optic pathway gliomas in neurofibromatosis. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2003.09.055

  50. Miller NR, Newman NJ, Biousse V, Kerrison JB (2004) Walsh and Hoyt’s clinical neuro-ophthalmology, 6th edn. Lippincott Williams & Wilkins (LWW), Philadelphia

    Google Scholar 

  51. Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, Rutka J, Buncic JR, Bouffet E (2009) Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 53:1231–1237. https://doi.org/10.1002/pbc.22198

    Article  PubMed  Google Scholar 

  52. Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Mizota A, Tormene AP (2016) ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol 133:1–9. https://doi.org/10.1007/s10633-016-9553-y

    Article  PubMed  Google Scholar 

  53. Packer RJ, Lange B, Ater J, Nicholson HS, Allen J, Walker R, Prados M, Jakacki R, Reaman G, Needles MN (1993) Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11:850–856. https://doi.org/10.1200/JCO.1993.11.5.850

    Article  CAS  PubMed  Google Scholar 

  54. Parrozzani R, Clementi M, Kotsafti O, Miglionico G, Trevisson E, Orlando G, Pilotto E, Midena E (2013) Optical coherence tomography in the diagnosis of optic pathway gliomas. Invest Ophthalmol Vis Sci 54:8112–8118. https://doi.org/10.1167/iovs.13-13093

    Article  PubMed  Google Scholar 

  55. Parrozzani R, Miglionico G, Leonardi F, Pulze S, Trevisson E, Clementi M, Opocher E, Licata V, Viscardi E, Pilotto E, Frizziero L, Midena E (2018) Correlation of peripapillary retinal nerve fibre layer thickness with visual acuity in paediatric patients affected by optic pathway glioma. Acta Ophthalmol 96:e1004–e1009. https://doi.org/10.1111/aos.13803

    Article  CAS  PubMed  Google Scholar 

  56. Patel DE, Cumberland PM, Walters BC, Russell I (2015) Study of optimal perimetric testing in children (OPTIC ): feasibility, reliability and repeatability of perimetry in children. 1–12. doi: https://doi.org/10.1371/journal.pone.0130895

  57. Pfäffli OA, Tamási B, Hanson JVM, Gerth-Kahlert C (2020) Colour vision testing in young children with reduced visual acuity. Acta Ophthalmol 98:e113–e120. https://doi.org/10.1111/aos.14219

    Article  PubMed  Google Scholar 

  58. Prada CE, Robert R, Hummel TR, Lovell AM, Hopkin RJ, Saal HM, Schorry EK (2015) The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis Type 1. J Pediatr. https://doi.org/10.1016/j.jpeds.2015.07.001

  59. Robert-Boire Bsc V, Rosca L, Samson Y, Ospina LH, Perreault S (2017) Clinical presentation and outcome of patients with optic pathway glioma. doi: https://doi.org/10.1016/j.pediatrneurol.2017.06.019

  60. Shofty B, Ben-Sira L, Freedman S, Yalon M, Dvir R, Weintraub M, Toledano H, Constantini S, Kesler A (2011) Visual outcome following chemotherapy for progressive optic pathway gliomas. Pediatr Blood Cancer 57:481–485. https://doi.org/10.1002/pbc

    Article  PubMed  Google Scholar 

  61. Shofty B, Constantini S, Bokstein F, Ram Z, Ben-Sira L, Freedman S, Vainer G, Kesler A (2014) Optic pathway gliomas in adults. Neurosurgery 74:273–279. https://doi.org/10.1227/NEU.0000000000000257

    Article  PubMed  Google Scholar 

  62. Shofty B, Mauda-Havakuk M, Weizman L, Constantini S, Ben-Bashat D, Dvir R, Pratt LT, Joskowicz L, Kesler A, Yalon M, Ravid L, Ben-Sira L (2015) The effect of chemotherapy on optic pathway gliomas and their sub-components: a volumetric MR analysis study. Pediatr Blood Cancer 62:1353–1359. https://doi.org/10.1002/pbc.25480

    Article  CAS  PubMed  Google Scholar 

  63. Shofty B, Weizman L, Joskowicz L, Constantini S, Kesler A, Ben-Bashat D, Yalon M, Dvir R, Freedman S, Roth J, Ben-Sira L (2011) MRI internal segmentation of optic pathway gliomas: clinical implementation of a novel algorithm. Childs Nerv Syst 27:1265–1272

    Article  Google Scholar 

  64. Shrestha RK, Shrestha GS (2015) Assessment of color vision among school children: a comparative study between the ishihara test and the farnsworth D-15 test. J Nepal Med Assoc 53:266–269. https://doi.org/10.31729/jnma.2743

    Article  CAS  Google Scholar 

  65. Shute RH, Westall CA (2000) Use of the Mollon-Reffin minimalist color vision test with young children. 366–372. doi: https://doi.org/10.1067/mpa.2000.110335

  66. Siatkowski RM (2006) VEP testing and visual pathway gliomas: not quite ready for prime time. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus 10:293–295

    Article  Google Scholar 

  67. Sigorini M, Zuccoli G, Ferrozzi F, Bacchini E, Street ME, Piazza P, Rossi M, Virdis R (2000) Magnetic resonance findings and ophthalmologic abnormalities are correlated in patients with neurofibromatosis type 1 (NF1). 272:269–272

  68. Singhal S, Birch JM, Kerr B, Lashford L, Evans DGR (2002) Neurofibromatosis type 1 and sporadic optic gliomas. Arch Dis Child 87:65–70. https://doi.org/10.1136/adc.87.1.65

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Stiebel-kalish H, Lusky M, Yassur Y, Kalish Y, Shuper A, Erlich R, Lubman S, Snir M (2004) Swedish interactive thresholding algorithm fast for following visual fields in prepubertal idiopathic intracranial. 1673–1675. doi: https://doi.org/10.1016/j.ophtha.2004.03.031

  70. Sylvester CL, Drohan LA, Sergott RC (2006) Optic-nerve gliomas, chiasmal gliomas and neurofibromatosis type 1. Curr Opin Ophthalmol 17:7–11. https://doi.org/10.1097/01.icu.0000193070.32369.37

    Article  PubMed  Google Scholar 

  71. Thiagalingam S, Flaherty M, Billson F, North K (2004) Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology. https://doi.org/10.1016/j.ophtha.2003.06.008

  72. Trevisson E, Cassina M, Opocher E, Vicenzi V, Lucchetta M, Parrozzani R, Miglionico G, Mardari R, Viscardi E, Midena E, Clementi M (2017) Natural history of optic pathway gliomas in a cohort of unselected patients affected by neurofibromatosis 1. J Neuro-Oncol 134:279–287. https://doi.org/10.1007/s11060-017-2517-6

    Article  Google Scholar 

  73. Trisciuzzi MTS, Riccardi R, Piccardi M, Iarossi G, Buzzonetti L, Dickmann A, Colosimo CJ, Ruggiero A, Di Rocco C, Falsini B (2004) A fast visual evoked potential method for functional assessment and follow-up of childhood optic gliomas. Clin Neurophysiol Off J Int Fed Clin Neurophysiol 115:217–226. https://doi.org/10.1016/s1388-2457(03)00282-7

    Article  Google Scholar 

  74. Tsang DS, Murphy ES, Merchant TE (2017) Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children. Int J Radiat Oncol Biol Phys 99:642–651. doi: https://doi.org/10.1016/j.ijrobp.2017.07.023

  75. Weizman L, Ben Sira L, Joskowicz L, Constantini S, Precel R, Shofty B, Ben Bashat D (2012) Automatic segmentation, internal classification, and follow-up of optic pathway gliomas in MRI. Med Image Anal 16:177–188. https://doi.org/10.1016/j.media.2011.07.001

    Article  CAS  PubMed  Google Scholar 

  76. Wolsey DH, Larson SA, Creel D, Hoffman R (2006) Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing? J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus 10:307–311. https://doi.org/10.1016/j.jaapos.2006.02.004

    Article  Google Scholar 

  77. Yanni SE, Wang J, Cheng CS, Locke KI, Wen Y, Birch DG, Birch EE (2013) Normative reference ranges for the retinal nerve fiber layer, macula, and retinal layer thicknesses in children. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2012.08.010

  78. Zahavi A, Toledano H, Cohen R, Sella S, Luckman J, Michowiz S, Goldenberg-Cohen N (2018) Use of optical coherence tomography to detect retinal nerve fiber loss in children with optic pathway glioma. Front Neurol 9. https://doi.org/10.3389/fneur.2018.01102

  79. Zeid JL, Charrow J, Sandu M, Goldman S, Listernick R (2006) Orbital optic nerve gliomas in children with neurofibromatosis type 1. J AAPOS. https://doi.org/10.1016/j.jaapos.2006.03.014

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    Daphna Mezad-Koursh, Anat Bachar Zipori, Dinah Zur, Lior Degabli, Meital Ben-Dov & Ainat Klein

  2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Daphna Mezad-Koursh, Anat Bachar Zipori, Dinah Zur, Lior Degabli, Meital Ben-Dov & Ainat Klein

Authors
  1. Daphna Mezad-Koursh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anat Bachar Zipori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dinah Zur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lior Degabli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Meital Ben-Dov
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ainat Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daphna Mezad-Koursh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(JPG 447 kb)

ESM 2

(JPG 1575 kb)

ESM 3

(JPG 1636 kb)

ESM 4

(DOCX 17 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mezad-Koursh, D., Bachar Zipori, A., Zur, D. et al. Visual function tests including the role of optical coherence tomography in neurofibromatosis 1. Childs Nerv Syst 36, 2363–2375 (2020). https://doi.org/10.1007/s00381-020-04706-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-020-04706-3

Keywords

Search

Navigation